News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
452,608 Results
Type
Article (25559)
Company Profile (101)
Press Release (426948)
Section
Business (159179)
Career Advice (2385)
Deals (25927)
Drug Delivery (76)
Drug Development (48894)
Employer Resources (140)
FDA (11142)
Job Trends (10288)
News (248582)
Policy (21960)
Tag
Academia (1851)
Alliances (31288)
Alzheimer's disease (875)
Approvals (11115)
Artificial intelligence (108)
Bankruptcy (212)
Best Places to Work (8436)
Biosimilars (81)
Breast cancer (124)
Cancer (917)
Cardiovascular disease (75)
Career advice (1959)
Cell therapy (193)
Clinical research (39596)
Collaboration (352)
Compensation (147)
COVID-19 (1923)
C-suite (76)
Data (967)
Diabetes (120)
Diagnostics (4748)
Earnings (89413)
Employer resources (121)
Events (53749)
Executive appointments (236)
FDA (11687)
Funding (279)
Gene therapy (145)
GLP-1 (418)
Government (3487)
Healthcare (13626)
Infectious disease (1994)
Inflammatory bowel disease (88)
Interviews (536)
IPO (13731)
Job creations (2105)
Job search strategy (1577)
Layoffs (325)
Legal (3865)
Lung cancer (142)
Manufacturing (191)
Medical device (9730)
Medtech (9732)
Mergers & acquisitions (12411)
Metabolic disorders (324)
Neuroscience (1115)
NextGen Class of 2024 (4581)
Non-profit (3213)
Northern California (1219)
Obesity (190)
Opinion (172)
Parkinson's disease (70)
Patents (75)
People (30481)
Phase I (11574)
Phase II (17365)
Phase III (14428)
Pipeline (464)
Postmarket research (1369)
Preclinical (4193)
Radiopharmaceuticals (168)
Rare diseases (185)
Real estate (3750)
Regulatory (15729)
Research institute (1613)
Resumes & cover letters (394)
Southern California (1106)
Startups (1951)
United States (10828)
Vaccines (435)
Weight loss (136)
Date
Today (102)
Last 7 days (412)
Last 30 days (1640)
Last 365 days (25260)
2024 (25154)
2023 (28832)
2022 (37504)
2021 (39242)
2020 (39471)
2019 (33140)
2018 (25486)
2017 (23928)
2016 (22179)
2015 (25458)
2014 (19169)
2013 (15528)
2012 (16759)
2011 (17168)
2010 (15053)
Location
Africa (584)
Arizona (96)
Asia (24901)
Australia (3816)
California (2772)
Canada (1044)
China (201)
Colorado (122)
Connecticut (125)
Europe (55099)
Florida (395)
Georgia (97)
Illinois (268)
Indiana (165)
Maryland (507)
Massachusetts (1945)
Michigan (123)
Minnesota (195)
New Jersey (839)
New York (808)
North Carolina (594)
Northern California (1219)
Ohio (94)
Pennsylvania (662)
South America (856)
Southern California (1106)
Texas (370)
Utah (85)
Washington State (275)
452,608 Results for "qu biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor
December 16, 2024
·
5 min read
Business
Qu Biologics and Foundation Medicine Collaborate to Impact the Care of Patients with Late-Stage Colorectal Cancer
Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators, a novel platform of immunotherapies designed to restore innate immune function, and Foundation Medicine, Inc. are pleased to announce a partnership aimed to impact the care of patients with late-stage colorectal cancer undergoing surgery.
June 6, 2024
·
4 min read
Business
Qu Biologics and TransBIOTech Awarded $450K Applied Research and Development Grant Funding
Qu Biologics Inc. is pleased to announce, in partnership with TransBIOTech (Quebec), being awarded an Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program administered through the Natural Sciences and Engineering.
March 11, 2024
·
5 min read
Qu Biologics Receives Accelerating Clinical Trial (ACT) Funding for PERIOP-06 Clinical Trial
Qu Biologics Inc. is pleased to announce that its Phase 2 clinical trial in late-stage colon cancer, PERIOP-06, was awarded CAD$400,000 in grant funding by the Accelerating Clinical Trial Canadian Consortium.
November 14, 2023
·
5 min read
Business
Dr. Matt Cahill Appointed Chief Operating Officer of Qu Biologics
Qu Biologics Inc. is pleased to announce the appointment of Matt Cahill MBA JD PhD, as Chief Operating Officer.
January 23, 2023
·
4 min read
Business
Qu Biologics and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of Qu Biologics’ First-in-Class Immunotherapy Platform
Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is excited to announce a new collaboration with Associate Professor Jonas Fuxe and his research team at the Karolinska Institute (KI) in Stockholm, Sweden, to characterize the molecular targets of Qu’s SSI therapy at the tissue level that lead to resolution of disease.
December 14, 2022
·
5 min read
Qu Biologics Closes USD$12M Equity Financing
Qu Biologics Inc. is pleased to announce the closing of a USD$12M equity financing to enable expansion of Qu’s team, initiation of an additional three Phase 2 clinical studies, and the acceleration of Qu’s novel immunomodulation platform.
March 21, 2022
·
3 min read
News
Webinar: Revolutionizing Biologics Discovery: Harnessing the Power of AI and Patent Data
This webinar explores the pivotal role of patent data in overcoming the data challenges faced by generative AI models in drug discovery, particularly for biologics. Watch now.
October 23, 2024
·
1 min read
·
BioSpace Insights
Press Releases
Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results
November 13, 2024
·
14 min read
Business
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB) today reported financial results and recent business highlights for its first quarter ended March 31, 2024.
May 15, 2024
·
13 min read
1 of 45,261
Next